Xvivo Perfusion ABXVIPF -1.32%87 EV-to-EBIT is 81.31 as of Jun. 29, 2026, which is 70% below its 10-year median of 269.31. GuruFocus rates XVIPF with a GF Score™ of 87/100 and a GF Value™ of $47.23 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks worse than 91.63% on this metric.
Xvivo Perfusion AB (OTCPK:XVIPF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Xvivo Perfusion AB's Enterprise Value for the quarter that ended in Mar. 2026 was $698.61 Mil.
Xvivo Perfusion AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB EV-to-EBIT Related Terms
Xvivo Perfusion AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Xvivo Perfusion AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's EV-to-EBIT falls into.
Xvivo Perfusion AB's current Enterprise Value is $816.60 Mil.
Xvivo Perfusion AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (XVIPF) has a EV-to-EBIT of 81.31 as of Jun. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Xvivo Perfusion AB and its competitors. This is 70% below median its historical median of 269.31. According to the industry distribution chart, Xvivo Perfusion AB ranks #427 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 91.6%.
Is Xvivo Perfusion AB's EV-to-EBIT too high?
Xvivo Perfusion AB's current EV-to-EBIT of 81.31 is 70% below median its 10-year median of 269.31. The Medical Devices & Instruments industry median EV-to-EBIT is 18.06. Xvivo Perfusion AB's value of 81.31 is 350.3% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #427 out of 466 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #427 out of 466 companies for EV-to-EBIT. This places Xvivo Perfusion AB in the lower half of its industry. The industry median EV-to-EBIT is 18.06. Xvivo Perfusion AB's value of 81.31 is 350.3% above this benchmark. While the company's 10-year median is 269.31 vs. the industry median of 18.06, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.06, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current EV-to-EBIT of 81.31 is 350.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current EV-to-EBIT is 81.31, which is 70% below median its own 10-year median of 269.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $47.23, compared to a current price of $29.00 — trading 38.6% below its estimated fair value. The current EV-to-EBIT is 81.31, which is 70% below median its 10-year median of 269.31 and 350.3% above the Medical Devices & Instruments industry median of 18.06. Xvivo Perfusion AB's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current EV-to-EBIT is 81.31 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 38.6% below its estimated GF Value™ of $47.23.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
EV-to-EBIT: 81.31 (70% below median its 10-year median of 269.31)
GF Value™: $47.23 vs. price of $29.00 (38.6% below fair value)
Industry Position: 350.3% above the Medical Devices & Instruments median (#427 of 466)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
87GF Score
Get the complete analysis for XVIPF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
